Insider Purchases: Inside the Buy
Tag: Funanc1al for Investors
Can Lyft Ever Lift Off or Will It Forever Uber-Underwhelm?
CEO David Risher has been scooping up Lyft shares like surge-priced burritos—and with record rides, rising cash flow, and a $750M buyback plan, the bullish case is stronger than ever. But can LYFT finally fly—or is Uber still driving the narrative?
Can Sweetgreen’s Stock Get Any Less Bitter?
Sweetgreen just served up its first insider buy since IPO—should investors take a bite? The fast-casual salad giant keeps growing but hasn’t turned a profit. We chop into the numbers, spice it up with fun, and toss in all the risks. 🥗📉
Xerox Holdings: This Company Still Exists—To Be or Not To Be... In Your Portfolio?
Xerox might feel like yesterday’s news, but insiders and institutions clearly disagree. With executives loading up on shares and a reinvention strategy underway, this classic name could be more than a relic—it might just be your next contrarian play. 📠💥
Can V.F. Corporation Face North and Land More Than Timber?
Insiders are buying, the CEO’s betting big, and the stitches are finally tightening at V.F. Corp. With a turnaround in motion and brands like Vans and Timberland in the mix, could this stock step back into fashion?
Penn Entertainment: A Double-Down That’s Finally Paying Off?
Penn Entertainment ($PENN) is showing signs of life — insiders are doubling down, revenues are climbing, and digital bets are growing fast. With shares rebounding, is it time to follow the high-rollers or step back from the table? 🎰📈
Middleby: Insiders Are Buying Like Something’s Cooking (and Not Just in the Kitchen…)
Insiders are grabbing shares of Middleby like fresh-baked cookies—$93M worth in May alone. With buybacks, spinoffs, and top-tier equipment across commercial, residential, and food processing, this stock may be more than a kitchen story. Is it time to take a bite?
Repay Holdings: Time to Reward the Patient Holder?
Insider buying is heating up at Repay Holdings. With over 200 institutions on board and a bargain-bin valuation, this fintech underdog might be getting ready to repay patient investors—with upside.
Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?
🏠 Douglas Elliman (DOUG): Luxury Real Estate, Budget Stock Price?
Insiders are buying big, the company’s cutting losses, and the cash pile is solid. Douglas Elliman might not be flashy, but it’s not flopping either. A low-priced luxury real estate play worth a look?